An overview of Semintra and why it is authorised in the EU
Semintra is a veterinary medicine used in cats to reduce proteinuria (protein in the urine) and to treat high blood pressure. Proteinuria can occur with chronic (long-term) kidney disease in cats, a common disease in elderly cats characterised by a progressive deterioration of kidney function over time. High blood pressure is also a long term problem of ageing cats which can occur with chronic kidney disease, hyperthyroidism (overactive thyroid gland) and other conditions.
Semintra : EPAR - Summary for the public (PDF/79.76 KB)
First published: 28/02/2013
Last updated: 25/06/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Boehringer Ingelheim Vetmedica GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
08/05/2018 Semintra - EMEA/V/C/002436 - X/0008
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Agents acting on the renin angiotensin system
angiotensin II antagonists
Reduction of proteinuria associated with chronic kidney disease (CKD).